Ahmedabad-based Cadila  Pharmaceuticals has announced the launch of a novel iron injection, a next-generation solution for addressing iron deficiency anaemia. The product will be available as Redshot FCM, fortified with the advanced Ferric Carboxymallose formulation, designed for administration to both adults and paediatric patients over one year of age, especially those with oral iron intolerance.

Redshot Injection stands out as an intravenous iron preparation that not only delivers effective amounts of iron but also boasts an exemplary safety profile. With superior tolerability and minimal to zero risk of anaphylaxis, Redshot accelerates the improvement of haemoglobin levels and efficiently replenishes depleted  iron  stores.  Offering  heightened  tolerability,  the  intravenous  delivery  of  iron  in  Redshot facilitates the utilization of high doses in a single administration.

Anaemia, characterised by impaired physical activities, general weakness, lethargy, and fatigue, often goes  unnoticed and is inadequately managed, particularly  in pregnancy, the  elderly  population, and cancer patients. Remarkably, Redshot addresses this gap, as anaemia is prevalent in cancer patients and has been linked to lower survival rates for those grappling with this deficiency. Anaemia in pregnancy, if not treated, can complicate childbirth and can put mothers and neonates at serious risks.